Welcome to our dedicated page for Organogenesis Holdings news (Ticker: ORGO), a resource for investors and traders seeking the latest updates and insights on Organogenesis Holdings stock.
Organogenesis Holdings Inc. (Nasdaq: ORGO) is a pioneering company in the field of regenerative medicine. Headquartered in Canton, Massachusetts, Organogenesis offers a diverse portfolio of bioactive and acellular biomaterial products, primarily targeting the Advanced Wound Care and Surgical & Sports Medicine markets. The company's innovative solutions cater to a wide range of patients with repair and regenerative needs.
The company's core products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, and Dermagraft, which are designed to improve patient outcomes while reducing overall healthcare costs. Organogenesis is recognized for its advancements in both orthopedics and spine treatments, reflecting its commitment to addressing unmet medical needs through cutting-edge research and development.
In recent news, Organogenesis has reported significant milestones and achievements. The company announced that its Phase 3 randomized control trial evaluating ReNu, a cryopreserved amniotic suspension allograft for knee osteoarthritis (OA), met its primary endpoint, demonstrating a significant reduction in knee OA pain. This achievement is poised to introduce new non-surgical treatment options for OA patients, potentially opening a significant market opportunity for Organogenesis.
The company has also faced challenges. Its third-quarter revenue was impacted by local coverage determination (LCD) issues, yet it managed to deliver substantial improvements in operating profitability and adjusted EBITDA. Organogenesis continues to build momentum with commercial support programs aimed at enhancing customer relationships and regaining lost accounts.
Financially, the company reported a net revenue of $99.7 million in the fourth quarter of 2023, reflecting a decrease from the previous year. Despite these hurdles, Organogenesis remains financially robust with $104.3 million in cash and equivalents as of December 2023. Its operating expenses have been carefully managed, showcasing a reduction in selling, general, and administrative expenses.
Looking ahead, Organogenesis has set optimistic projections for 2024, with anticipated revenue growth driven by new product launches and the continued demonstration of value to customers. The company is also planning to further engage with regulatory bodies to secure approvals and expand the clinical indications of its products.
Overall, Organogenesis Holdings Inc. stands out for its commitment to innovation, patient care, and financial stability, making it a significant player in the regenerative medicine landscape. For more information, visit their official website.
Organogenesis announced its participation as a leading sponsor at the 2022 Symposium on Advanced Wound Care (SAWC) Spring Conference in Phoenix, Arizona, from April 6-10, 2022. The company will present new research on its wound care products, including PuraPly® AM and Apligraf®. Key events include a breakfast symposium on randomized controlled trials and an Innovation Theatre lunch discussing chronic wound treatment. Attendees can visit booth #703 for insights into the latest advanced wound care solutions.
Organogenesis Holdings Inc. (Nasdaq: ORGO) will announce its first quarter fiscal 2022 financial results after market close on May 10th. Following the announcement, management will host a conference call at 5:00 p.m. ET to discuss the results and provide a corporate update, including a Q&A session. Participants can join by dialing 866-795-3142 or 409-937-8908 for international calls, using access code 3349739. A live webcast will also be available on the company's investor relations website, with an archive accessible for one year.
Organogenesis Holdings Inc. (Nasdaq: ORGO) will participate in Oppenheimer’s 32nd Annual Healthcare Conference on March 15-16, 2022. The management team is scheduled to present on March 15 at 10:40 a.m. Eastern Time. A live audio webcast of the presentation will be available on the company’s website, with a replay accessible for 30 days afterwards. Organogenesis focuses on regenerative medicine, offering advanced wound care and surgical products designed to meet various patient needs.
Organogenesis Holdings reported robust financial results for Q4 2021 and the fiscal year ending December 31, 2021. Q4 net revenue reached $128.6 million, a 20% increase from Q4 2020, mainly driven by a 30% growth in Advanced Wound Care products. Total net revenue for 2021 was $468.1 million, a 38% rise year-over-year. Net income soared to $51.7 million in Q4, compared to $18.3 million a year earlier. The company forecasted revenue for 2022 between $485 million and $515 million, indicating a expected growth of 4% to 10%.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has appointed Michael J. Driscoll, Ed.D. to its Board of Directors, effective February 15, 2022. Dr. Driscoll, an independent director, will contribute to the Audit and Nominating Committees. He brings extensive experience with 28 years in the financial services sector and 10 years in academia. His previous roles include dean of Mount St. Mary’s University and a senior executive at Adelphi University. The company's management expressed confidence in his strategic insights to bolster its operations in regenerative medicine.
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leader in regenerative medicine, will participate in two upcoming investor conferences. Management will engage in a virtual fireside chat on February 16 at 1:30 p.m. ET during the BTIG Virtual MedTech Conference. Additionally, they will partake in another virtual chat on February 18 at 8:40 a.m. ET for the 11th Annual SVB Leerink Global Healthcare Conference. Live webcasts will be accessible via the respective conference websites, with the second's archive available for 30 days post-event.
Organogenesis Holdings (Nasdaq: ORGO) will announce its fourth quarter and fiscal year 2021 financial results on March 1, 2022, after market close. Management will discuss these results in a conference call at 5:00 p.m. ET, which is open to participants via a dedicated phone line or a live webcast on the investor relations section of their website. A replay will be available for two weeks post-call. Organogenesis specializes in regenerative medicine, focusing on solutions for advanced wound care and surgical and sports medicine.
Organogenesis Holdings Inc. (Nasdaq: ORGO) announced the appointment of Prathyusha Duraibabu to its Board of Directors as of November 19, 2021. Ms. Duraibabu brings over 24 years of expertise in technology and healthcare, having held senior roles at global biotechnology firms. Currently the CFO of Sangamo Therapeutics, she has also served as Corporate Controller at Pacific Biosciences. The addition is expected to enhance the Board's strategic insight and oversight, particularly within the Audit Committee.
Organogenesis Holdings Inc. (Nasdaq: ORGO) reported Q3 2021 net revenue of $113.8 million, a 13% increase year-over-year. Advanced Wound Care products drove revenue growth, contributing $107.3 million, up 19% compared to Q3 2020. However, Surgical & Sports Medicine revenue fell 41% to $6.4 million. Net income decreased to $12.6 million from $20.8 million in Q3 2020. Operating expenses rose 30% to $71.3 million, impacting profitability. The company forecasts 2021 net revenue between $458 million and $470 million, a 35% to 39% increase year-over-year.
FAQ
What is the current stock price of Organogenesis Holdings (ORGO)?
What is the market cap of Organogenesis Holdings (ORGO)?
What is Organogenesis Holdings Inc.?
Where is Organogenesis Holdings Inc. headquartered?
What are some of the core products of Organogenesis?
What recent achievement has Organogenesis announced?
How did Organogenesis perform financially in the fourth quarter of 2023?
What are the future prospects for Organogenesis?
What markets does Organogenesis target?
What is the significance of ReNu in Organogenesis's portfolio?
How does Organogenesis contribute to healthcare cost reduction?
Where can more information about Organogenesis be found?
